Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Abstract Background The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regime...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Springer 2024-11-01
Serie:	Cancer Immunology, Immunotherapy
Soggetti:	Combination therapy Hepatocellular carcinoma Lenvatinib Sintilimab Transarterial chemoembolization (TACE)
Accesso online:	https://doi.org/10.1007/s00262-024-03857-5
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!